Ocrevus and Raynaud's phenomenon - a phase IV clinical study of FDA data

Summary:

Raynaud's phenomenon is reported as a side effect among people who take Ocrevus (ocrelizumab), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Sertraline, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Raynaud's phenomenon when taking Ocrevus. It is created by eHealthMe based on reports of 56,539 people who have side effects when taking Ocrevus from the FDA, and is updated regularly.

What is Ocrevus?

Ocrevus has active ingredients of ocrelizumab. eHealthMe is studying from 56,583 Ocrevus users. Check the latest studies of Ocrevus.

What is Raynaud's phenomenon?

Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas) is found to be associated with 626 drugs and 996 conditions by eHealthMe. Check the latest studies of Raynaud's phenomenon.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 31, 2026

56,539 people reported to have side effects when taking Ocrevus.
Among them, 64 people (0.11%) have Raynaud's phenomenon.

Could Ocrevus cause Raynaud's phenomenon?

Among these 64 people:

How long have people been on Ocrevus when they have Raynaud's phenomenon? *

  • < 1 month: 66.67 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 33.33 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Raynaud's phenomenon when taking Ocrevus? *

  • female: 98.44 %
  • male: 1.56 %

What is the age of people who have Raynaud's phenomenon when taking Ocrevus? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 31.11 %
  • 30-39: 2.22 %
  • 40-49: 11.11 %
  • 50-59: 55.56 %
  • 60+: 0.0 %

What are other drugs people take besides Ocrevus? *

  1. Sertraline: 24 people, 37.50%
  2. Pregabalin: 17 people, 26.56%
  3. Ramipril: 17 people, 26.56%
  4. Levothyroxine Sodium: 15 people, 23.44%
  5. Gabapentin: 8 people, 12.50%
  6. Baclofen: 5 people, 7.81%
  7. Ozempic: 5 people, 7.81%
  8. Advil: 4 people, 6.25%
  9. Aspirin: 4 people, 6.25%
  10. Concerta: 3 people, 4.69%

What are other side effects people have besides Raynaud's phenomenon? *

  1. Fatigue (feeling of tiredness): 44 people, 68.75%
  2. Joint Pain: 37 people, 57.81%
  3. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 34 people, 53.12%
  4. Pain: 34 people, 53.12%
  5. Rashes (redness): 33 people, 51.56%
  6. Hypoaesthesia (reduced sense of touch or sensation): 32 people, 50.00%
  7. High Blood Pressure: 31 people, 48.44%
  8. Muscle Disorder (muscle disease): 29 people, 45.31%
  9. Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 29 people, 45.31%
  10. Drug Ineffective: 29 people, 45.31%

What are the existing conditions these people have? *

  1. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 29 people, 45.31%
  2. Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 27 people, 42.19%
  3. Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 24 people, 37.50%
  4. Pain: 3 people, 4.69%
  5. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 4.69%
  6. Fatigue (feeling of tiredness): 3 people, 4.69%
  7. Muscle Spasms (muscle contraction): 2 people, 3.12%
  8. Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 1.56%
  9. Automatic Bladder (nerve impulses between the bladder and the spinal cord remain intact and the bladder can be trained to empty by reflex (spastic) action): 1 person, 1.56%
  10. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 1.56%

* Approximation only. Some reports may have incomplete information.

Do you take Ocrevus and have Raynaud's phenomenon?

- Check whether Raynaud's phenomenon is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ocrevus:

Raynaud's phenomenon treatments and more:

How severe was Raynaud's phenomenon and when was it recovered:

Expand to all the drugs that have ingredients of ocrelizumab:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Raynaud's phenomenon:

Browse all the conditions that are associated with Raynaud's phenomenon:


How the study uses the data?

The study uses data from the FDA. It is based on ocrelizumab (the active ingredients of Ocrevus) and Ocrevus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: